- Vaccine Ontology ID: VO_0004725
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Vector: ALVAC vaccine vector
- Preparation: Recombinant canarypox virus vector (ALVAC-AHSV) co-expressing synthetic genes encoding the outer capsid proteins (VP2 and VP5) of AHSV serotype 4 (AHSV-4) (Guthrie et al., 2009).
- Immunization Route: Intramuscular injection (i.m.)
|
- Vaccine Ontology ID: VO_0004758
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Vector: Modified Vaccinia Ankara (MVA) virus vaccine vector
- Preparation: Recombinant vaccine based on modified vaccinia Ankara expressing AHS-4 VP2 (MVA-VP2) (Castillo-Olivares et al., 2011).
- Immunization Route: Intramuscular injection (i.m.)
|
Guthrie et al., 2009: Guthrie AJ, Quan M, Lourens CW, Audonnet JC, Minke JM, Yao J, He L, Nordgren R, Gardner IA, Maclachlan NJ. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus. Vaccine. 2009; 27(33); 4434-4438. [PubMed: 19490959].
|
Castillo-Olivares et al., 2011: Castillo-Olivares J, Calvo-Pinilla E, Casanova I, Bachanek-Bankowska K, Chiam R, Maan S, Nieto JM, Ortego J, Mertens PP. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model. PloS one. 2011; 6(1); e16503. [PubMed: 21298069].
|
